Abstract
Background Although COVID-19 vaccines are currently under use in pregnant and postpartum women, there is still lack of evidence regarding safety and effectiveness in these populations. This study aims to describe the safety profile of COVID-19 vaccines in pregnant and postpartum women in the early stage of vaccination campaign in Brazil.
Methods This is an observational cross-sectional study using data from the Brazilian surveillance information system for adverse events (SI-EAPV) to characterize the safety of COVID-19 vaccines available (Sinovac/Butantan, Pfizer/BioNTech, AstraZeneca and Janssen) in Brazilian pregnant and postpartum women after receiving it from April to August 2021. A descriptive analysis was performed to assess the frequency and incidence rate of the adverse events (AE) for COVID-19 vaccines.
Results A total of 3,333 adverse events following COVID-19 immunization were reported for the study population in the SIEAPV. The incidence of AE found was 309.4/100,000 doses (95% CI 297.23, 321.51). Regarding the four vaccines available in the country, Sinovac/Butantan had the lowest incidence (74.08/100,000 doses; 95% CI 63.47, 84.69). Systemic events were the most frequent notified for the group (82.07%), followed by local (11.93%) and maternal (4.74%), being most of them classified as non-severe (90.65%).
Conclusion A similar pattern of AE as stated in other studies was found, with even better results for non-viral vector vaccines, corroborating to the recommendation of vaccination for these groups. Even though, further studies appraising a longer observation time are still needed to provide a broader safety aspect for the vaccines currently under use for this population.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: RGP, RVF, AJLA, GSJ and CZD are employees of IQVIA Brazil which was contracted by Sinovac Life Sciences to conduct the study. YPQ, XM, WDY are employees of Sinovac Life Sciences.
Funding Statement
This study was funded by Sinovac Life Sciences.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki. Datasets used were public and anonymized, protecting the confidentiality and privacy of all patients. All activities were conducted according to the applicable Brazilian federal laws. Based on the resolution 510/ 2016 from the National Brazilian Ethical Committee, studies using secondary anonymized databases do not require ethical approval. In that sense, this study involves only openly available human data, which were obtained from the Brazilian Ministry of Health, using the Fala BR platform (https://www.gov.br/acessoainformacao/pt-br/falabr), in agreement with Brazilian transparency law and General Data Protection Regulation. Also, the National Vaccination Campaign against COVID-19 database were used (https://opendatasus.saude.gov.br/). This anonymized dataset is provided by The Brazilian Ministry of Health for research purposes.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
qiaoyp6109{at}sinovac.com (Y.P.Q.); mengx{at}sinovac.com (X.M.); yinwd{at}sinovac.com (W.D.Y.)
ariane.dejesuslopesdeabreu{at}iqvia.com (A.J.L.A.); carolina.zampirolli{at}iqvia.com (C.Z.D.); rafaela.ferreira{at}iqvia.com (R.V.F.); rpereira2{at}br.imshealth.com (R.G.P.); guilherme.julian{at}iqvia.com (G.S.J.)
Data Availability
All data produced are available online at Fala BR platform and Opendatasus websites.
